Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a cardiovascular medical device company that entered the public markets through a business combination with Health Assurance Acquisition Corp (HAAC), a healthcare-focused special purpose acquisition company that completed its initial public offering in 2020 and was sponsored by Health Assurance Acquisition Corp, LLC. The company filed its 10-K annual report on January 25, 2023, representing one of its earliest annual disclosures as a combined public entity following the de-SPAC transaction. Orchestra BioMed is developing cardiac and vascular device programs targeting hypertension and coronary artery disease. For the full filing history and SPAC deal data on OBIO, sign up for SpacDesk.